Wed, May 14, 9:32 PM (39 days ago)
**Coeptis Therapeutics Holdings, Inc. (COEP) Q1 2025 Financial Summary** **Financial Health:** - **Cash Position:** Increased to $4.27 million from $1.03 million in Q1 2024. - **Total Assets:** $13.45 million, up from $8.91 million. - **Total Liabilities:** $5.99 million, increased from $5.04 million. - **Stockholders' Equity:** $7.46 million, up from $3.87 million. **Performance Metrics:** - **Revenue:** Generated $62.87 thousand in Q1 2025, compared to no revenue in Q1 2024. - **Gross Profit:** $17.72 thousand, with a gross margin of approximately 28.19%. - **Net Loss:** $3.42 million, slightly higher than the $3.00 million loss in Q1 2024. - **Operating Expenses:** Increased to $4.07 million from $2.92 million, driven by higher professional services and stock-based compensation. **Cash Flow:** - **Operating Cash Flow:** Negative $2.37 million, improved from negative $1.90 million. - **Investing Cash Flow:** No significant investing activities. - **Financing Cash Flow:** Positive $6.10 million, driven by proceeds from notes payable and preferred stock offering. **Earnings Changes:** - **Earnings per Share (EPS):** Basic and diluted loss of $1.11 per share, compared to $0.08 in Q1 2024. **Quarterly Performance Discussion:** - **Revenue Growth:** Achieved initial revenue from data research and advertising campaigns. - **Expense Management:** Increased expenses due to strategic financing costs, stock-based compensation, and professional services. - **Cash Flow Improvement:** Significant increase in cash position due to financing activities. **Trends and Uncertainties:** - **Revenue Trends:** Minimal revenue expected in the near term, focusing on product development and capital raising. - **Operating Expenses:** Anticipated increase in general and administrative expenses, research and development costs. - **Future Operations:** Continued focus on biopharmaceutical and technology segments, with strategic partnerships and acquisitions. **Future Operations Impact:** - **Biotechnology Segment:** Continued development of cell therapy technologies for cancer and other diseases. - **Technology Segment:** Expansion of AI-powered marketing software and robotic process automation capabilities. - **Capital Raising:** Ongoing efforts to raise additional capital through equity and debt financing. **Ticker:** COEP